nodes	percent_of_prediction	percent_of_DWPC	metapath
Salicylate-sodium—Acetylsalicylic acid—TP53—liver cancer	0.0131	0.469	CrCbGaD
Salicylate-sodium—Faecaloma—Epirubicin—liver cancer	0.0124	0.0199	CcSEcCtD
Salicylate-sodium—Faecalith—Epirubicin—liver cancer	0.0124	0.0199	CcSEcCtD
Salicylate-sodium—Faecaloma—Doxorubicin—liver cancer	0.0114	0.0184	CcSEcCtD
Salicylate-sodium—Faecalith—Doxorubicin—liver cancer	0.0114	0.0184	CcSEcCtD
Salicylate-sodium—Warmth—Epirubicin—liver cancer	0.0111	0.0179	CcSEcCtD
Salicylate-sodium—Hypocalcaemia—Sorafenib—liver cancer	0.0104	0.0168	CcSEcCtD
Salicylate-sodium—Hyperphosphataemia—Epirubicin—liver cancer	0.0103	0.0166	CcSEcCtD
Salicylate-sodium—Warmth—Doxorubicin—liver cancer	0.0103	0.0165	CcSEcCtD
Salicylate-sodium—Hyperphosphataemia—Doxorubicin—liver cancer	0.00956	0.0154	CcSEcCtD
Salicylate-sodium—Skin exfoliation—Sorafenib—liver cancer	0.00912	0.0147	CcSEcCtD
Salicylate-sodium—Cardiac failure congestive—Sorafenib—liver cancer	0.00764	0.0123	CcSEcCtD
Salicylate-sodium—Renal failure acute—Sorafenib—liver cancer	0.00751	0.0121	CcSEcCtD
Salicylate-sodium—Mesalazine—PPARG—liver cancer	0.00703	0.253	CrCbGaD
Salicylate-sodium—Hypernatraemia—Epirubicin—liver cancer	0.00671	0.0108	CcSEcCtD
Salicylate-sodium—Venous thrombosis—Epirubicin—liver cancer	0.00654	0.0105	CcSEcCtD
Salicylate-sodium—Dehydration—Sorafenib—liver cancer	0.00645	0.0104	CcSEcCtD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—EPT1—liver cancer	0.0064	0.0182	CbGpPWpGaD
Salicylate-sodium—Abdominal pain upper—Sorafenib—liver cancer	0.00633	0.0102	CcSEcCtD
Salicylate-sodium—Hypokalaemia—Sorafenib—liver cancer	0.00631	0.0102	CcSEcCtD
Salicylate-sodium—Hypernatraemia—Doxorubicin—liver cancer	0.00621	0.01	CcSEcCtD
Salicylate-sodium—Gastric ulcer—Epirubicin—liver cancer	0.00607	0.00977	CcSEcCtD
Salicylate-sodium—Venous thrombosis—Doxorubicin—liver cancer	0.00605	0.00974	CcSEcCtD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—HMOX1—liver cancer	0.00601	0.0171	CbGpPWpGaD
Salicylate-sodium—Dysphagia—Sorafenib—liver cancer	0.00599	0.00964	CcSEcCtD
Salicylate-sodium—Abdominal discomfort—Sorafenib—liver cancer	0.00574	0.00924	CcSEcCtD
Salicylate-sodium—PTGS1—Eicosanoid Synthesis—GGT1—liver cancer	0.00562	0.016	CbGpPWpGaD
Salicylate-sodium—Gastric ulcer—Doxorubicin—liver cancer	0.00562	0.00904	CcSEcCtD
Salicylate-sodium—Acute coronary syndrome—Sorafenib—liver cancer	0.00527	0.00848	CcSEcCtD
Salicylate-sodium—Renal failure—Sorafenib—liver cancer	0.00525	0.00845	CcSEcCtD
Salicylate-sodium—Myocardial infarction—Sorafenib—liver cancer	0.00524	0.00843	CcSEcCtD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—EPT1—liver cancer	0.00508	0.0145	CbGpPWpGaD
Salicylate-sodium—Burning sensation—Epirubicin—liver cancer	0.00508	0.00818	CcSEcCtD
Salicylate-sodium—Epistaxis—Sorafenib—liver cancer	0.00504	0.00811	CcSEcCtD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—HMOX1—liver cancer	0.00477	0.0136	CbGpPWpGaD
Salicylate-sodium—Burning sensation—Doxorubicin—liver cancer	0.0047	0.00756	CcSEcCtD
Salicylate-sodium—Erythema multiforme—Sorafenib—liver cancer	0.00453	0.0073	CcSEcCtD
Salicylate-sodium—Necrosis—Epirubicin—liver cancer	0.0045	0.00724	CcSEcCtD
Salicylate-sodium—Feeling hot—Epirubicin—liver cancer	0.0045	0.00724	CcSEcCtD
Salicylate-sodium—Tinnitus—Sorafenib—liver cancer	0.00447	0.0072	CcSEcCtD
Salicylate-sodium—PTGS2—Eicosanoid Synthesis—GGT1—liver cancer	0.00446	0.0127	CbGpPWpGaD
Salicylate-sodium—Abscess—Epirubicin—liver cancer	0.00446	0.00718	CcSEcCtD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.00438	0.0125	CbGpPWpGaD
Salicylate-sodium—Stinging—Epirubicin—liver cancer	0.00436	0.00701	CcSEcCtD
Salicylate-sodium—Arrhythmia—Sorafenib—liver cancer	0.00428	0.00689	CcSEcCtD
Salicylate-sodium—PTGS1—Arachidonic acid metabolism—HPGDS—liver cancer	0.00418	0.0119	CbGpPWpGaD
Salicylate-sodium—Erythema—Sorafenib—liver cancer	0.00418	0.00672	CcSEcCtD
Salicylate-sodium—Necrosis—Doxorubicin—liver cancer	0.00416	0.0067	CcSEcCtD
Salicylate-sodium—Feeling hot—Doxorubicin—liver cancer	0.00416	0.0067	CcSEcCtD
Salicylate-sodium—Abscess—Doxorubicin—liver cancer	0.00413	0.00664	CcSEcCtD
Salicylate-sodium—Dysgeusia—Sorafenib—liver cancer	0.00409	0.00658	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—AHR—liver cancer	0.00406	0.0116	CbGpPWpGaD
Salicylate-sodium—Extravasation—Epirubicin—liver cancer	0.00405	0.00651	CcSEcCtD
Salicylate-sodium—Stinging—Doxorubicin—liver cancer	0.00403	0.00649	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—UGDH—liver cancer	0.00398	0.0114	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—NFE2L2—liver cancer	0.00395	0.0113	CbGpPWpGaD
Salicylate-sodium—Cellulitis—Epirubicin—liver cancer	0.00388	0.00625	CcSEcCtD
Salicylate-sodium—Hypocalcaemia—Epirubicin—liver cancer	0.00386	0.0062	CcSEcCtD
Salicylate-sodium—Oliguria—Epirubicin—liver cancer	0.00383	0.00616	CcSEcCtD
Salicylate-sodium—Syncope—Sorafenib—liver cancer	0.00374	0.00603	CcSEcCtD
Salicylate-sodium—Extravasation—Doxorubicin—liver cancer	0.00374	0.00602	CcSEcCtD
Salicylate-sodium—Ulcer—Epirubicin—liver cancer	0.00373	0.00601	CcSEcCtD
Salicylate-sodium—Creatinine increased—Epirubicin—liver cancer	0.00371	0.00597	CcSEcCtD
Salicylate-sodium—Loss of consciousness—Sorafenib—liver cancer	0.00367	0.00591	CcSEcCtD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—PIK3CD—liver cancer	0.00365	0.0104	CbGpPWpGaD
Salicylate-sodium—Cellulitis—Doxorubicin—liver cancer	0.00359	0.00578	CcSEcCtD
Salicylate-sodium—Magnesium salicylate—ALB—liver cancer	0.00359	0.129	CrCbGaD
Salicylate-sodium—PTGS2—S1P1 pathway—KDR—liver cancer	0.00358	0.0102	CbGpPWpGaD
Salicylate-sodium—Hypocalcaemia—Doxorubicin—liver cancer	0.00357	0.00574	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—liver cancer	0.00354	0.0101	CbGpPWpGaD
Salicylate-sodium—Oliguria—Doxorubicin—liver cancer	0.00354	0.0057	CcSEcCtD
Salicylate-sodium—PTGS2—Spinal Cord Injury—EFNB2—liver cancer	0.00348	0.00993	CbGpPWpGaD
Salicylate-sodium—Ulcer—Doxorubicin—liver cancer	0.00345	0.00556	CcSEcCtD
Salicylate-sodium—Creatinine increased—Doxorubicin—liver cancer	0.00343	0.00552	CcSEcCtD
Salicylate-sodium—Anaphylactic shock—Sorafenib—liver cancer	0.00341	0.00548	CcSEcCtD
Salicylate-sodium—Infection—Sorafenib—liver cancer	0.00339	0.00545	CcSEcCtD
Salicylate-sodium—Skin exfoliation—Epirubicin—liver cancer	0.00337	0.00542	CcSEcCtD
Salicylate-sodium—Shock—Sorafenib—liver cancer	0.00335	0.00539	CcSEcCtD
Salicylate-sodium—Fluid retention—Epirubicin—liver cancer	0.00335	0.00539	CcSEcCtD
Salicylate-sodium—Blood urea increased—Epirubicin—liver cancer	0.00333	0.00536	CcSEcCtD
Salicylate-sodium—PTGS2—Arachidonic acid metabolism—HPGDS—liver cancer	0.00332	0.00946	CbGpPWpGaD
Salicylate-sodium—Anorexia—Sorafenib—liver cancer	0.00325	0.00523	CcSEcCtD
Salicylate-sodium—Oesophagitis—Epirubicin—liver cancer	0.00323	0.00519	CcSEcCtD
Salicylate-sodium—Ecchymosis—Epirubicin—liver cancer	0.00319	0.00514	CcSEcCtD
Salicylate-sodium—PTGS2—Calcium signaling in the CD4+ TCR pathway—CSF2—liver cancer	0.00313	0.00893	CbGpPWpGaD
Salicylate-sodium—PTGS1—Arachidonic acid metabolism—GGT1—liver cancer	0.00313	0.00891	CbGpPWpGaD
Salicylate-sodium—Skin exfoliation—Doxorubicin—liver cancer	0.00312	0.00502	CcSEcCtD
Salicylate-sodium—Fluid retention—Doxorubicin—liver cancer	0.0031	0.00499	CcSEcCtD
Salicylate-sodium—Blood urea increased—Doxorubicin—liver cancer	0.00308	0.00496	CcSEcCtD
Salicylate-sodium—Sepsis—Epirubicin—liver cancer	0.00306	0.00493	CcSEcCtD
Salicylate-sodium—Dyspnoea—Sorafenib—liver cancer	0.00304	0.00489	CcSEcCtD
Salicylate-sodium—Dyspepsia—Sorafenib—liver cancer	0.003	0.00483	CcSEcCtD
Salicylate-sodium—Oesophagitis—Doxorubicin—liver cancer	0.00298	0.0048	CcSEcCtD
Salicylate-sodium—Phlebitis—Epirubicin—liver cancer	0.00297	0.00479	CcSEcCtD
Salicylate-sodium—Decreased appetite—Sorafenib—liver cancer	0.00296	0.00477	CcSEcCtD
Salicylate-sodium—Ecchymosis—Doxorubicin—liver cancer	0.00295	0.00475	CcSEcCtD
Salicylate-sodium—Fatigue—Sorafenib—liver cancer	0.00294	0.00473	CcSEcCtD
Salicylate-sodium—Constipation—Sorafenib—liver cancer	0.00291	0.00469	CcSEcCtD
Salicylate-sodium—Pain—Sorafenib—liver cancer	0.00291	0.00469	CcSEcCtD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—PIK3CD—liver cancer	0.0029	0.00827	CbGpPWpGaD
Salicylate-sodium—Sepsis—Doxorubicin—liver cancer	0.00283	0.00456	CcSEcCtD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—GPX3—liver cancer	0.00283	0.00806	CbGpPWpGaD
Salicylate-sodium—Cardiac failure congestive—Epirubicin—liver cancer	0.00283	0.00455	CcSEcCtD
Salicylate-sodium—Gastrointestinal pain—Sorafenib—liver cancer	0.00279	0.00448	CcSEcCtD
Salicylate-sodium—Renal failure acute—Epirubicin—liver cancer	0.00278	0.00447	CcSEcCtD
Salicylate-sodium—Phlebitis—Doxorubicin—liver cancer	0.00275	0.00443	CcSEcCtD
Salicylate-sodium—Urticaria—Sorafenib—liver cancer	0.00271	0.00436	CcSEcCtD
Salicylate-sodium—Abdominal pain—Sorafenib—liver cancer	0.00269	0.00433	CcSEcCtD
Salicylate-sodium—Body temperature increased—Sorafenib—liver cancer	0.00269	0.00433	CcSEcCtD
Salicylate-sodium—Renal impairment—Epirubicin—liver cancer	0.00269	0.00433	CcSEcCtD
Salicylate-sodium—Lethargy—Epirubicin—liver cancer	0.00261	0.00421	CcSEcCtD
Salicylate-sodium—Cerebrovascular accident—Epirubicin—liver cancer	0.00261	0.00421	CcSEcCtD
Salicylate-sodium—Cardiac failure congestive—Doxorubicin—liver cancer	0.00261	0.00421	CcSEcCtD
Salicylate-sodium—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—liver cancer	0.00259	0.00739	CbGpPWpGaD
Salicylate-sodium—Renal failure acute—Doxorubicin—liver cancer	0.00257	0.00413	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Sorafenib—liver cancer	0.00251	0.00404	CcSEcCtD
Salicylate-sodium—Renal impairment—Doxorubicin—liver cancer	0.00249	0.00401	CcSEcCtD
Salicylate-sodium—PTGS2—Arachidonic acid metabolism—GGT1—liver cancer	0.00248	0.00708	CbGpPWpGaD
Salicylate-sodium—PTGS1—Arachidonic acid metabolism—CYP1A1—liver cancer	0.00245	0.00698	CbGpPWpGaD
Salicylate-sodium—Asthenia—Sorafenib—liver cancer	0.00244	0.00393	CcSEcCtD
Salicylate-sodium—Cerebrovascular accident—Doxorubicin—liver cancer	0.00242	0.00389	CcSEcCtD
Salicylate-sodium—Lethargy—Doxorubicin—liver cancer	0.00242	0.00389	CcSEcCtD
Salicylate-sodium—Pruritus—Sorafenib—liver cancer	0.00241	0.00388	CcSEcCtD
Salicylate-sodium—Blood creatinine increased—Epirubicin—liver cancer	0.0024	0.00386	CcSEcCtD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.00239	0.0068	CbGpPWpGaD
Salicylate-sodium—Dehydration—Epirubicin—liver cancer	0.00238	0.00383	CcSEcCtD
Salicylate-sodium—Abdominal pain upper—Epirubicin—liver cancer	0.00234	0.00377	CcSEcCtD
Salicylate-sodium—Hypokalaemia—Epirubicin—liver cancer	0.00233	0.00375	CcSEcCtD
Salicylate-sodium—Diarrhoea—Sorafenib—liver cancer	0.00233	0.00375	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—NR1H4—liver cancer	0.00233	0.00663	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—GSTA3—liver cancer	0.00229	0.00652	CbGpPWpGaD
Salicylate-sodium—Acetylsalicylic acid—ALB—liver cancer	0.00228	0.0818	CrCbGaD
Salicylate-sodium—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—liver cancer	0.00226	0.00645	CbGpPWpGaD
Salicylate-sodium—Dizziness—Sorafenib—liver cancer	0.00225	0.00363	CcSEcCtD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—GPX3—liver cancer	0.00224	0.0064	CbGpPWpGaD
Salicylate-sodium—Abdominal distension—Epirubicin—liver cancer	0.00223	0.00359	CcSEcCtD
Salicylate-sodium—Blood creatinine increased—Doxorubicin—liver cancer	0.00222	0.00357	CcSEcCtD
Salicylate-sodium—Asthma—Epirubicin—liver cancer	0.00221	0.00356	CcSEcCtD
Salicylate-sodium—Dysphagia—Epirubicin—liver cancer	0.00221	0.00356	CcSEcCtD
Salicylate-sodium—Dehydration—Doxorubicin—liver cancer	0.0022	0.00355	CcSEcCtD
Salicylate-sodium—PTGS2—Signaling mediated by p38-alpha and p38-beta—MAPK14—liver cancer	0.00218	0.00622	CbGpPWpGaD
Salicylate-sodium—Vomiting—Sorafenib—liver cancer	0.00217	0.00349	CcSEcCtD
Salicylate-sodium—Abdominal pain upper—Doxorubicin—liver cancer	0.00217	0.00348	CcSEcCtD
Salicylate-sodium—Hypokalaemia—Doxorubicin—liver cancer	0.00216	0.00347	CcSEcCtD
Salicylate-sodium—Rash—Sorafenib—liver cancer	0.00215	0.00346	CcSEcCtD
Salicylate-sodium—Dermatitis—Sorafenib—liver cancer	0.00215	0.00345	CcSEcCtD
Salicylate-sodium—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—liver cancer	0.00214	0.0061	CbGpPWpGaD
Salicylate-sodium—Headache—Sorafenib—liver cancer	0.00213	0.00344	CcSEcCtD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—TNF—liver cancer	0.00213	0.00607	CbGpPWpGaD
Salicylate-sodium—Bronchitis—Epirubicin—liver cancer	0.00213	0.00343	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—GSTA4—liver cancer	0.00209	0.00596	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—CYP1A1—liver cancer	0.00208	0.00592	CbGpPWpGaD
Salicylate-sodium—Abdominal distension—Doxorubicin—liver cancer	0.00206	0.00332	CcSEcCtD
Salicylate-sodium—Asthma—Doxorubicin—liver cancer	0.00205	0.0033	CcSEcCtD
Salicylate-sodium—Dysphagia—Doxorubicin—liver cancer	0.00205	0.0033	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—GSTA2—liver cancer	0.00204	0.00581	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CSF2—liver cancer	0.00203	0.00578	CbGpPWpGaD
Salicylate-sodium—Nausea—Sorafenib—liver cancer	0.00202	0.00326	CcSEcCtD
Salicylate-sodium—Weight increased—Epirubicin—liver cancer	0.00202	0.00324	CcSEcCtD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—GGT1—liver cancer	0.00199	0.00567	CbGpPWpGaD
Salicylate-sodium—Drowsiness—Epirubicin—liver cancer	0.00197	0.00318	CcSEcCtD
Salicylate-sodium—PTGS2—S1P1 pathway—VEGFA—liver cancer	0.00197	0.00563	CbGpPWpGaD
Salicylate-sodium—Bronchitis—Doxorubicin—liver cancer	0.00197	0.00317	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—GSTA1—liver cancer	0.00197	0.00561	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—NAT2—liver cancer	0.00194	0.00555	CbGpPWpGaD
Salicylate-sodium—PTGS2—Arachidonic acid metabolism—CYP1A1—liver cancer	0.00194	0.00554	CbGpPWpGaD
Salicylate-sodium—Renal failure—Epirubicin—liver cancer	0.00194	0.00312	CcSEcCtD
Salicylate-sodium—Salicylic acid—ALB—liver cancer	0.00188	0.0674	CrCbGaD
Salicylate-sodium—Weight increased—Doxorubicin—liver cancer	0.00186	0.003	CcSEcCtD
Salicylate-sodium—Epistaxis—Epirubicin—liver cancer	0.00186	0.003	CcSEcCtD
Salicylate-sodium—Drowsiness—Doxorubicin—liver cancer	0.00183	0.00294	CcSEcCtD
Salicylate-sodium—Renal failure—Doxorubicin—liver cancer	0.0018	0.00289	CcSEcCtD
Salicylate-sodium—Hepatitis—Epirubicin—liver cancer	0.00177	0.00285	CcSEcCtD
Salicylate-sodium—Hypoaesthesia—Epirubicin—liver cancer	0.00176	0.00284	CcSEcCtD
Salicylate-sodium—Epistaxis—Doxorubicin—liver cancer	0.00172	0.00277	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—ESR1—liver cancer	0.00172	0.00491	CbGpPWpGaD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—IL6—liver cancer	0.00172	0.0049	CbGpPWpGaD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.00171	0.00489	CbGpPWpGaD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—TNF—liver cancer	0.00169	0.00482	CbGpPWpGaD
Salicylate-sodium—Erythema multiforme—Epirubicin—liver cancer	0.00168	0.0027	CcSEcCtD
Salicylate-sodium—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—liver cancer	0.00166	0.00472	CbGpPWpGaD
Salicylate-sodium—Tinnitus—Epirubicin—liver cancer	0.00165	0.00266	CcSEcCtD
Salicylate-sodium—Hepatitis—Doxorubicin—liver cancer	0.00164	0.00264	CcSEcCtD
Salicylate-sodium—Hypoaesthesia—Doxorubicin—liver cancer	0.00163	0.00263	CcSEcCtD
Salicylate-sodium—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—liver cancer	0.00161	0.00459	CbGpPWpGaD
Salicylate-sodium—Arrhythmia—Epirubicin—liver cancer	0.00158	0.00255	CcSEcCtD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—GGT1—liver cancer	0.00158	0.0045	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—HPGDS—liver cancer	0.00155	0.00443	CbGpPWpGaD
Salicylate-sodium—Erythema multiforme—Doxorubicin—liver cancer	0.00155	0.0025	CcSEcCtD
Salicylate-sodium—Erythema—Epirubicin—liver cancer	0.00154	0.00248	CcSEcCtD
Salicylate-sodium—Tinnitus—Doxorubicin—liver cancer	0.00153	0.00246	CcSEcCtD
Salicylate-sodium—Flatulence—Epirubicin—liver cancer	0.00152	0.00245	CcSEcCtD
Salicylate-sodium—Dysgeusia—Epirubicin—liver cancer	0.00151	0.00243	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—FST—liver cancer	0.00149	0.00424	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—liver cancer	0.00147	0.00419	CbGpPWpGaD
Salicylate-sodium—Arrhythmia—Doxorubicin—liver cancer	0.00147	0.00236	CcSEcCtD
Salicylate-sodium—Vision blurred—Epirubicin—liver cancer	0.00145	0.00234	CcSEcCtD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—MTHFR—liver cancer	0.00145	0.00414	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.00144	0.0041	CbGpPWpGaD
Salicylate-sodium—Erythema—Doxorubicin—liver cancer	0.00143	0.0023	CcSEcCtD
Salicylate-sodium—Flatulence—Doxorubicin—liver cancer	0.00141	0.00226	CcSEcCtD
Salicylate-sodium—Dysgeusia—Doxorubicin—liver cancer	0.0014	0.00225	CcSEcCtD
Salicylate-sodium—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—liver cancer	0.00139	0.00395	CbGpPWpGaD
Salicylate-sodium—Syncope—Epirubicin—liver cancer	0.00138	0.00223	CcSEcCtD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—IL6—liver cancer	0.00136	0.00389	CbGpPWpGaD
Salicylate-sodium—Palpitations—Epirubicin—liver cancer	0.00136	0.00219	CcSEcCtD
Salicylate-sodium—Loss of consciousness—Epirubicin—liver cancer	0.00136	0.00218	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—GSTM1—liver cancer	0.00135	0.00386	CbGpPWpGaD
Salicylate-sodium—Vision blurred—Doxorubicin—liver cancer	0.00135	0.00217	CcSEcCtD
Salicylate-sodium—Convulsion—Epirubicin—liver cancer	0.00134	0.00215	CcSEcCtD
Salicylate-sodium—Chest pain—Epirubicin—liver cancer	0.00131	0.00211	CcSEcCtD
Salicylate-sodium—Anxiety—Epirubicin—liver cancer	0.00131	0.00211	CcSEcCtD
Salicylate-sodium—Syncope—Doxorubicin—liver cancer	0.00128	0.00206	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—RAF1—liver cancer	0.00128	0.00364	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—F2—liver cancer	0.00127	0.00363	CbGpPWpGaD
Salicylate-sodium—Confusional state—Epirubicin—liver cancer	0.00127	0.00204	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—CYP2E1—liver cancer	0.00127	0.00361	CbGpPWpGaD
Salicylate-sodium—Palpitations—Doxorubicin—liver cancer	0.00126	0.00203	CcSEcCtD
Salicylate-sodium—Oedema—Epirubicin—liver cancer	0.00126	0.00203	CcSEcCtD
Salicylate-sodium—Anaphylactic shock—Epirubicin—liver cancer	0.00126	0.00203	CcSEcCtD
Salicylate-sodium—Loss of consciousness—Doxorubicin—liver cancer	0.00125	0.00202	CcSEcCtD
Salicylate-sodium—Infection—Epirubicin—liver cancer	0.00125	0.00201	CcSEcCtD
Salicylate-sodium—Shock—Epirubicin—liver cancer	0.00124	0.00199	CcSEcCtD
Salicylate-sodium—Convulsion—Doxorubicin—liver cancer	0.00124	0.00199	CcSEcCtD
Salicylate-sodium—Tachycardia—Epirubicin—liver cancer	0.00123	0.00198	CcSEcCtD
Salicylate-sodium—Hyperhidrosis—Epirubicin—liver cancer	0.00122	0.00196	CcSEcCtD
Salicylate-sodium—Chest pain—Doxorubicin—liver cancer	0.00122	0.00196	CcSEcCtD
Salicylate-sodium—Anxiety—Doxorubicin—liver cancer	0.00121	0.00195	CcSEcCtD
Salicylate-sodium—Anorexia—Epirubicin—liver cancer	0.0012	0.00193	CcSEcCtD
Salicylate-sodium—Hypotension—Epirubicin—liver cancer	0.00118	0.00189	CcSEcCtD
Salicylate-sodium—Confusional state—Doxorubicin—liver cancer	0.00117	0.00189	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—liver cancer	0.00117	0.00333	CbGpPWpGaD
Salicylate-sodium—Oedema—Doxorubicin—liver cancer	0.00117	0.00188	CcSEcCtD
Salicylate-sodium—Anaphylactic shock—Doxorubicin—liver cancer	0.00117	0.00188	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—GGT1—liver cancer	0.00116	0.00332	CbGpPWpGaD
Salicylate-sodium—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—liver cancer	0.00116	0.00331	CbGpPWpGaD
Salicylate-sodium—Infection—Doxorubicin—liver cancer	0.00116	0.00186	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—HNF4A—liver cancer	0.00116	0.0033	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—MTHFR—liver cancer	0.00115	0.00328	CbGpPWpGaD
Salicylate-sodium—Shock—Doxorubicin—liver cancer	0.00115	0.00184	CcSEcCtD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.00114	0.00325	CbGpPWpGaD
Salicylate-sodium—Tachycardia—Doxorubicin—liver cancer	0.00114	0.00183	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	0.00113	0.00324	CbGpPWpGaD
Salicylate-sodium—Paraesthesia—Epirubicin—liver cancer	0.00113	0.00182	CcSEcCtD
Salicylate-sodium—Hyperhidrosis—Doxorubicin—liver cancer	0.00113	0.00181	CcSEcCtD
Salicylate-sodium—Dyspnoea—Epirubicin—liver cancer	0.00112	0.00181	CcSEcCtD
Salicylate-sodium—Somnolence—Epirubicin—liver cancer	0.00112	0.0018	CcSEcCtD
Salicylate-sodium—Anorexia—Doxorubicin—liver cancer	0.00111	0.00179	CcSEcCtD
Salicylate-sodium—Dyspepsia—Epirubicin—liver cancer	0.00111	0.00178	CcSEcCtD
Salicylate-sodium—Decreased appetite—Epirubicin—liver cancer	0.00109	0.00176	CcSEcCtD
Salicylate-sodium—Hypotension—Doxorubicin—liver cancer	0.00109	0.00175	CcSEcCtD
Salicylate-sodium—Fatigue—Epirubicin—liver cancer	0.00109	0.00175	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	0.00108	0.00308	CbGpPWpGaD
Salicylate-sodium—Pain—Epirubicin—liver cancer	0.00108	0.00173	CcSEcCtD
Salicylate-sodium—Constipation—Epirubicin—liver cancer	0.00108	0.00173	CcSEcCtD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—liver cancer	0.00107	0.00306	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—liver cancer	0.00107	0.00305	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—SERPINE1—liver cancer	0.00106	0.00302	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—ALB—liver cancer	0.00106	0.00302	CbGpPWpGaD
Salicylate-sodium—Paraesthesia—Doxorubicin—liver cancer	0.00105	0.00168	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—GSTP1—liver cancer	0.00105	0.00298	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—liver cancer	0.00104	0.00297	CbGpPWpGaD
Salicylate-sodium—Dyspnoea—Doxorubicin—liver cancer	0.00104	0.00167	CcSEcCtD
Salicylate-sodium—Feeling abnormal—Epirubicin—liver cancer	0.00104	0.00167	CcSEcCtD
Salicylate-sodium—Somnolence—Doxorubicin—liver cancer	0.00104	0.00167	CcSEcCtD
Salicylate-sodium—Gastrointestinal pain—Epirubicin—liver cancer	0.00103	0.00166	CcSEcCtD
Salicylate-sodium—Dyspepsia—Doxorubicin—liver cancer	0.00103	0.00165	CcSEcCtD
Salicylate-sodium—Decreased appetite—Doxorubicin—liver cancer	0.00101	0.00163	CcSEcCtD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—F2—liver cancer	0.00101	0.00288	CbGpPWpGaD
Salicylate-sodium—Fatigue—Doxorubicin—liver cancer	0.001	0.00162	CcSEcCtD
Salicylate-sodium—PTGS2—Disease—APCS—liver cancer	0.001	0.00286	CbGpPWpGaD
Salicylate-sodium—Urticaria—Epirubicin—liver cancer	0.001	0.00161	CcSEcCtD
Salicylate-sodium—Pain—Doxorubicin—liver cancer	0.000996	0.0016	CcSEcCtD
Salicylate-sodium—Constipation—Doxorubicin—liver cancer	0.000996	0.0016	CcSEcCtD
Salicylate-sodium—Abdominal pain—Epirubicin—liver cancer	0.000996	0.0016	CcSEcCtD
Salicylate-sodium—Body temperature increased—Epirubicin—liver cancer	0.000996	0.0016	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	0.000973	0.00277	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—GSTM1—liver cancer	0.000961	0.00274	CbGpPWpGaD
Salicylate-sodium—Feeling abnormal—Doxorubicin—liver cancer	0.00096	0.00155	CcSEcCtD
Salicylate-sodium—Gastrointestinal pain—Doxorubicin—liver cancer	0.000953	0.00153	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Epirubicin—liver cancer	0.000928	0.00149	CcSEcCtD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000926	0.00264	CbGpPWpGaD
Salicylate-sodium—Urticaria—Doxorubicin—liver cancer	0.000926	0.00149	CcSEcCtD
Salicylate-sodium—Body temperature increased—Doxorubicin—liver cancer	0.000921	0.00148	CcSEcCtD
Salicylate-sodium—Abdominal pain—Doxorubicin—liver cancer	0.000921	0.00148	CcSEcCtD
Salicylate-sodium—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—liver cancer	0.000914	0.00261	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—CYP1A1—liver cancer	0.000911	0.0026	CbGpPWpGaD
Salicylate-sodium—Asthenia—Epirubicin—liver cancer	0.000904	0.00145	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—MYC—liver cancer	0.000895	0.00255	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000893	0.00255	CbGpPWpGaD
Salicylate-sodium—Pruritus—Epirubicin—liver cancer	0.000891	0.00143	CcSEcCtD
Salicylate-sodium—Diarrhoea—Epirubicin—liver cancer	0.000862	0.00139	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Doxorubicin—liver cancer	0.000858	0.00138	CcSEcCtD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—SERPINE1—liver cancer	0.000842	0.0024	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—ALB—liver cancer	0.00084	0.00239	CbGpPWpGaD
Salicylate-sodium—Asthenia—Doxorubicin—liver cancer	0.000836	0.00135	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—TNF—liver cancer	0.000834	0.00238	CbGpPWpGaD
Salicylate-sodium—Dizziness—Epirubicin—liver cancer	0.000833	0.00134	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	0.000827	0.00236	CbGpPWpGaD
Salicylate-sodium—Pruritus—Doxorubicin—liver cancer	0.000824	0.00133	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CDKN2A—liver cancer	0.000816	0.00233	CbGpPWpGaD
Salicylate-sodium—Vomiting—Epirubicin—liver cancer	0.000801	0.00129	CcSEcCtD
Salicylate-sodium—Diarrhoea—Doxorubicin—liver cancer	0.000797	0.00128	CcSEcCtD
Salicylate-sodium—Rash—Epirubicin—liver cancer	0.000794	0.00128	CcSEcCtD
Salicylate-sodium—Dermatitis—Epirubicin—liver cancer	0.000793	0.00128	CcSEcCtD
Salicylate-sodium—Headache—Epirubicin—liver cancer	0.000789	0.00127	CcSEcCtD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—liver cancer	0.00078	0.00222	CbGpPWpGaD
Salicylate-sodium—Dizziness—Doxorubicin—liver cancer	0.000771	0.00124	CcSEcCtD
Salicylate-sodium—Nausea—Epirubicin—liver cancer	0.000748	0.0012	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	0.000746	0.00213	CbGpPWpGaD
Salicylate-sodium—Vomiting—Doxorubicin—liver cancer	0.000741	0.00119	CcSEcCtD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000735	0.0021	CbGpPWpGaD
Salicylate-sodium—Rash—Doxorubicin—liver cancer	0.000735	0.00118	CcSEcCtD
Salicylate-sodium—Dermatitis—Doxorubicin—liver cancer	0.000734	0.00118	CcSEcCtD
Salicylate-sodium—Headache—Doxorubicin—liver cancer	0.00073	0.00117	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CDKN1B—liver cancer	0.000722	0.00206	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000709	0.00202	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	0.000703	0.002	CbGpPWpGaD
Salicylate-sodium—Nausea—Doxorubicin—liver cancer	0.000692	0.00111	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CCND1—liver cancer	0.000689	0.00196	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000683	0.00195	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—UGDH—liver cancer	0.000681	0.00194	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CDKN1A—liver cancer	0.000667	0.0019	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—EPT1—liver cancer	0.00064	0.00183	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.00064	0.00182	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—TNF—liver cancer	0.000625	0.00178	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—TAT—liver cancer	0.000607	0.00173	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000597	0.0017	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000561	0.0016	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—MYC—liver cancer	0.000553	0.00158	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.000551	0.00157	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—CDKN1B—liver cancer	0.00055	0.00157	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000542	0.00155	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—UGDH—liver cancer	0.000541	0.00154	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—CASP3—liver cancer	0.000539	0.00154	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—IL2—liver cancer	0.000539	0.00154	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—CCND1—liver cancer	0.000525	0.0015	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000521	0.00148	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—KRAS—liver cancer	0.000511	0.00146	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—MMP9—liver cancer	0.00051	0.00145	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—EPT1—liver cancer	0.000508	0.00145	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—IL6—liver cancer	0.000504	0.00144	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—TNF—liver cancer	0.000496	0.00141	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—TAT—liver cancer	0.000482	0.00137	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000474	0.00135	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.000447	0.00127	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—HRAS—liver cancer	0.000434	0.00124	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—MYC—liver cancer	0.000421	0.0012	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—TGFB1—liver cancer	0.00042	0.0012	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CPT1B—liver cancer	0.000413	0.00118	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GLUL—liver cancer	0.000413	0.00118	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.000409	0.00117	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—IL6—liver cancer	0.0004	0.00114	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—NR1H4—liver cancer	0.000398	0.00113	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—TNF—liver cancer	0.000392	0.00112	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTA3—liver cancer	0.000391	0.00112	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—LTF—liver cancer	0.000391	0.00112	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.000374	0.00107	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.000367	0.00105	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTA4—liver cancer	0.000358	0.00102	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.000357	0.00102	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.000356	0.00102	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.000355	0.00101	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.000354	0.00101	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	0.00035	0.000997	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTA2—liver cancer	0.000349	0.000994	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—TP53—liver cancer	0.000346	0.000986	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.000346	0.000985	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	0.000337	0.000962	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTA1—liver cancer	0.000336	0.000959	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—NAT2—liver cancer	0.000333	0.000948	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GLUL—liver cancer	0.000328	0.000934	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CPT1B—liver cancer	0.000328	0.000934	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PPARA—liver cancer	0.00032	0.000912	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—ALDOB—liver cancer	0.000319	0.000909	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—IL6—liver cancer	0.000317	0.000903	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—NR1H4—liver cancer	0.000316	0.000901	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	0.000311	0.000888	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTA3—liver cancer	0.000311	0.000885	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CRABP1—liver cancer	0.000304	0.000867	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—ALDOB—liver cancer	0.000302	0.000862	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	0.000286	0.000817	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	0.000286	0.000815	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTA4—liver cancer	0.000284	0.00081	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	0.000278	0.000791	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTA2—liver cancer	0.000277	0.000789	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	0.000274	0.000781	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTA1—liver cancer	0.000267	0.000761	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	0.000267	0.000761	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—HPGDS—liver cancer	0.000266	0.000758	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	0.000265	0.000755	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PPARG—liver cancer	0.000264	0.000754	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—NAT2—liver cancer	0.000264	0.000753	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	0.000254	0.000724	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—ALDOB—liver cancer	0.000253	0.000722	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	0.000243	0.000693	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CRABP1—liver cancer	0.000241	0.000689	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	0.000241	0.000686	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—ADAM17—liver cancer	0.000239	0.000681	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—ALB—liver cancer	0.000238	0.000678	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PSMD10—liver cancer	0.000237	0.000676	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PSMA4—liver cancer	0.000237	0.000676	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	0.000235	0.000671	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GOT2—liver cancer	0.000231	0.000657	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PSMD10—liver cancer	0.000225	0.00064	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PSMA4—liver cancer	0.000225	0.00064	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—GOT2—liver cancer	0.000219	0.000623	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	0.000217	0.00062	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CYP2E1—liver cancer	0.000217	0.000618	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—HPGDS—liver cancer	0.000211	0.000602	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	0.00021	0.000598	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	0.00021	0.000598	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CYCS—liver cancer	0.000203	0.000578	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GGT1—liver cancer	0.000199	0.000567	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GOT1—liver cancer	0.000199	0.000567	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	0.000199	0.000566	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	0.000191	0.000545	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—ALB—liver cancer	0.000189	0.000538	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—GOT1—liver cancer	0.000189	0.000538	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PSMD10—liver cancer	0.000188	0.000536	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PSMA4—liver cancer	0.000188	0.000536	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GOT2—liver cancer	0.000183	0.000522	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTP1—liver cancer	0.000179	0.00051	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—HMOX1—liver cancer	0.000176	0.000503	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PRKCE—liver cancer	0.000174	0.000496	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CYP2E1—liver cancer	0.000172	0.000491	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	0.000167	0.000475	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTM1—liver cancer	0.000164	0.000468	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CYCS—liver cancer	0.000161	0.000459	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GGT1—liver cancer	0.000158	0.00045	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GOT1—liver cancer	0.000158	0.00045	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CYP1A1—liver cancer	0.000156	0.000444	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—H2AFX—liver cancer	0.000152	0.000433	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—MTHFR—liver cancer	0.000145	0.000414	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PPARA—liver cancer	0.000142	0.000406	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTP1—liver cancer	0.000142	0.000405	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—HMOX1—liver cancer	0.00014	0.000399	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—MTHFR—liver cancer	0.000138	0.000392	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—TERT—liver cancer	0.000137	0.000391	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTM1—liver cancer	0.00013	0.000372	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	0.000128	0.000365	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CYP1A1—liver cancer	0.000124	0.000352	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PIK3CG—liver cancer	0.000122	0.000348	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PPARG—liver cancer	0.000118	0.000336	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—APC—liver cancer	0.000116	0.00033	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—MTHFR—liver cancer	0.000115	0.000329	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PPARA—liver cancer	0.000113	0.000322	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—BRAF—liver cancer	0.000109	0.00031	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PIK3CD—liver cancer	0.000107	0.000306	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—ALB—liver cancer	0.000106	0.000302	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PIK3CD—liver cancer	0.000102	0.00029	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	0.000102	0.00029	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—SERPINE1—liver cancer	0.000101	0.000287	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PIK3CG—liver cancer	9.68e-05	0.000276	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PIK3CB—liver cancer	9.35e-05	0.000266	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PPARG—liver cancer	9.35e-05	0.000266	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—RAF1—liver cancer	9.07e-05	0.000259	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PIK3CB—liver cancer	8.86e-05	0.000253	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—MTOR—liver cancer	8.86e-05	0.000253	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PIK3CD—liver cancer	8.51e-05	0.000243	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—ALB—liver cancer	8.4e-05	0.00024	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—CDKN1B—liver cancer	8.31e-05	0.000237	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—CTNNB1—liver cancer	7.85e-05	0.000224	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—CDKN1A—liver cancer	7.67e-05	0.000219	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PIK3CB—liver cancer	7.42e-05	0.000212	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—STAT3—liver cancer	6.85e-05	0.000195	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—MYC—liver cancer	6.36e-05	0.000181	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—TGFB1—liver cancer	6.35e-05	0.000181	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—KRAS—liver cancer	5.88e-05	0.000168	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PIK3CA—liver cancer	5.7e-05	0.000162	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PIK3CA—liver cancer	5.4e-05	0.000154	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—HRAS—liver cancer	5e-05	0.000142	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—IL6—liver cancer	4.78e-05	0.000136	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—AKT1—liver cancer	4.65e-05	0.000133	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PIK3CA—liver cancer	4.52e-05	0.000129	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—AKT1—liver cancer	4.41e-05	0.000126	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—AKT1—liver cancer	3.69e-05	0.000105	CbGpPWpGaD
